Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 6/20 | 0.54 |
| ▸ | DPP9 | Q86TI2 | 6/20 | 0.54 |
| ▸ | DPP4 | P27487 | 4/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.33 |
| ▸ | CTSC | P53634 | 3/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL77561 | 1.00 | DPP8 (0.54) | DPP8DPP9DPP4ALOX15BLM | |
| SCHEMBL1600752 | 0.94 | DPP4 (0.49) | DPP8DPP9DPP4ALOX15BLM | |
| SCHEMBL2182958 | 0.92 | DPP4 (0.48) | DPP8DPP9DPP4ALOX15BLM | |
| SCHEMBL11136056 | 0.90 | DPP4 (0.51) | DPP8DPP9DPP4ALOX15BLM | |
| SCHEMBL2182616 | 0.89 | DPP4 (0.46) | DPP8DPP9DPP4ALOX15BLM | |
| SCHEMBL11649721 | 0.88 | DPP4 (0.50) | DPP8DPP9DPP4ALOX15BLM | |
| SCHEMBL11649726 | 0.88 | DPP4 (0.50) | DPP8DPP9DPP4ALOX15BLM | |
| SCHEMBL10728037 | 0.88 | DPP4 (0.43) | DPP8DPP9DPP4ALOX15BLM | |
| SCHEMBL2192330 | 0.88 | DPP8 (0.45) | DPP8DPP9DPP4ALOX15BLM | |
| SCHEMBL6255984 | 0.88 | DPP8 (0.47) | DPP8DPP9DPP4ALOX15BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2082041-B1 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2018-03-14 | — | — | EP | disclosed |
| EP-2432314-B1 | MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE | PROBIODRUG AG (DE) | 2017-12-20 | — | — | EP | disclosed |
| US-9462793-B2 | Mouse carrying a knock-out mutation of the Qpct-gene | PROBIODRUG AG (DE) | 2016-10-11 | — | — | US | disclosed |
| EP-2581449-B1 | Novel genes related to glutaminyl cyclase | PROBIODRUG AG (DE) | 2016-09-14 | — | — | EP | disclosed |
| US-9277737-B2 | Mouse models carrying a knock-out mutation of the QPCTL-gene | PROBIODRUG AG (DE) | 2016-03-08 | — | — | US | disclosed |
| EP-2195336-B1 | TRANSGENIC MICE | PROBIODRUG AG (DE) | 2015-01-21 | — | — | EP | disclosed |
| EP-1675578-B9 | INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES FOR THE TREATMENT OF THE NEURODEGENERATIVE DISEASES FBD AND FDD | PROBIODRUG AG (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-8647834-B2 | Screening method for enzyme inhibitors | PROBIODRUG AG (DE) | 2014-02-11 | — | — | US | disclosed |
| US-20130291133-A1 | MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE QPCTL-GENE | PROBIODRUG AG (DE) | 2013-10-31 | — | — | US | disclosed |
| EP-2238252-B1 | MOUSE MODELS CARRYING A KNOCK-OUT MUTATION OF THE GLUTAMINYL CYCLASE GENE | PROBIODRUG AG (DE) | 2013-07-31 | — | — | EP | disclosed |
| US-20080200567-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS | PROBIODRUG AG (DE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008087197-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS | PROBIODRUG AG (DE) | 2008-07-24 | — | — | WO | disclosed |
| US-7381537-B2 | Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease | PROBIODRUG AG (DE) | 2008-06-03 | — | — | US | disclosed |
| WO-2008034891-A2 | NOVEL GENES RELATED TO GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-03-27 | — | — | WO | disclosed |
| US-20060189523-A1 | Use of effectors of glutaminyl and glutamate cyclases | PROBIODRUG AG (DE) | 2006-08-24 | — | — | US | disclosed |
| EP-1675578-A2 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | Probiodrug AG (DE) | 2006-07-05 | — | — | EP | disclosed |
| EP-1620082-A2 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005039548-A2 | USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2005-05-06 | — | — | WO | disclosed |
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | PROBIODRUG AG (DE) | 2005-03-17 | — | — | US | disclosed |
| WO-2004098625-A2 | MEDICAL USE OF INHIBITORS OF GLUTAMINYL AND GLUTAMATE CYCLASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189523-A1 | Use of effectors of glutaminyl and glutamate cyclases | GLS, GLUL, GLS2 | DPP8 3636/4885DPP9 2668/4885DPP4 1981/4885 |
| US-20080200567-A1 | IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS | QPCT, PCYT1A, PSEN2 | DPP8 3733/4885DPP9 4061/4885DPP4 4178/4885 |
| US-20050058635-A1 | Anticancer agents; therapy for infections; administering glutaminyl cyclase inhibitor; Alzheimer's disease; Down syndrome; controlling fertility; schizophrenia; skin disorders | GLS, QPCT, GLS2 | DPP8 1336/4885DPP9 905/4885DPP4 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.